Study to Evaluate D-1553 in Subjects With Solid Tumors
A phase 1/2 trial of Garsorasib, Cetuximab and Pembrolizumab in non-small-cell lung cancer, run by InventisBio Co., Ltd, active and no longer recruiting.
Overview
Study to Evaluate D-1553 in Subjects With Solid Tumors is a phase 1/2 interventional study registered as NCT04585035 by InventisBio Co., Ltd, with 180 participants enrolled, started 2020-10-02 and due to reach its primary completion in 2024-04-30. Interventions recorded: D-1553 and D-1553 in combination with Drug: pembrolizumab, Drug:KEYTRUDA® , Drug: cetuximab, Drug: other.
Similar pages
not linked directly; found by shared links- TrialStudy to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors
Shares InventisBio, Garsorasib and the tag pipeline.
- TrialStudy of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)
Shares Cetuximab, Merck & Co. (MSD), Pembrolizumab and the tag pipeline.
- TrialKEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Shares Cetuximab, Merck & Co. (MSD), Pembrolizumab and the tag pipeline.
- TrialStudy of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
Shares Merck & Co. (MSD), Pembrolizumab, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Shares Merck & Co. (MSD), Pembrolizumab, Non-small-cell lung cancer and the tag pipeline.
- Triala Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors
Shares InventisBio and the tag pipeline.
- TrialA Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
Shares Cetuximab, Merck & Co. (MSD) and the tag pipeline.
- TrialStudy of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Shares Cetuximab, Merck & Co. (MSD), Pembrolizumab, Non-small-cell lung cancer and the tag pipeline.